CV Outcomes in Diabetes

Risk reduction with antihyperglycaemic therapies


Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).


The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycaemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.


CV specialists are well-positioned to play a key role in managing patients with T2D, including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycaemic agents into routine practice.

Close X
Other videos you might like

Section Advisor

Professor Mikhail N Kosiborod

Saint Luke's America Heart Institute, Kansas City, MO, US

The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.

Recent Videos


ESC 2021 Discussion: The FIGARO-DKD Trial
Bertram Pitt, Harriette Van Spall


ESC 2021 Discussion: The EMPEROR-Preserved Trial
Stefan Anker, Harriette Van Spall

Video Series

SGLT2i Updates 2021
Stefan Anker, Shelley Zieroth, Andrew JS Coats


ACC 21: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF
Deepak Bhatt, Harriette Van Spall


AHA 2020 Discussion: The SCORED Study
Harriette Van Spall, Deepak Bhatt


AHA 2020: EMPA-TROPISM Trial Results